Nanogen, Elitech deal

The companies will reverse-merge, combining Nanogen’s molecular and point-of-care diagnostics with Elitech’s in vitro diagnostics for the clinical chemistry and microbiology markets. Elitech shareholders will

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE